Overview

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.

Phase:

Phase 2

Details

Lead Sponsor:

Grupo Espanol de Tumores Neuroendocrinos

Collaborator:

MFAR

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab